Information  X 
Enter a valid email address

Nucleus Financial Gp (NUC)

  Print      Mail a friend

Tuesday 25 September, 2018

Nucleus Financial Gp

Director/PDMR Shareholding (Replacement)

RNS Number : 8788B
Nucleus Financial Group PLC
25 September 2018
 

 

The announcement originally released on 25/09/18 at 11.23am under RNS No 8523B has been amended.  Amendment has been identified with an asterisk (*).

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

Nucleus Financial Group plc

("Nucleus")

Director share purchase

Nucleus (AIM: NUC) announces that, pursuant to the notification obligations in accordance with Article 19 of the Market Abuse Regulation (MAR), it has received notification that on 21 September 2018, Angus Samuels, Non-executive Chairman, purchased 26,704 ordinary shares of 0.1p each ("Ordinary Shares") for an average price of 176p. As a result, Mr Samuels is interested in 26,704 Ordinary Shares, representing 0.03% of the Company's issued share capital. 

The Company has also been notified of an acquisition of ordinary shares by the spouse of Angus Samuels, Non-executive chairman, Katy Samuels, a "person closely associated" for the purposes of MAR.

1.

Details of PDMR / person closely associated with them ('PCA')

a)

Name

James Anthony Angus Samuels

2.

Details of PDMR / person closely associated with them ('PCA')

a)

Position / status

Non-executive company chairman

b)

Initial notification / amendment

Initial notification *

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nucleus Financial Group plc

b)

LEI

213800MAIAI3M7LM5950

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

c)

Description of the financial instrument

Ordinary shares of 0.1p

 

ISIN: GB00BG226J60

d)

Nature of the transaction

Acquisition

e)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.76

26,704

 

f)

Aggregated information

 

Aggregated volume

 

Price

 

 

26,704

 

£46,999.04

 

g)

Date of the transaction

21 September 2018

 

h)

Place of the transaction

LONDON STOCK EXCHANGE XLON

 

       

 

3.

Details of PDMR / person closely associated with them ('PCA')

a)

Name

Katy Samuels

4.

Details of PDMR / person closely associated with them ('PCA')

a)

Position / status

PCA

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nucleus Financial Group plc

b)

LEI

213800MAIAI3M7LM5950

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

c)

Description of the financial instrument

Ordinary shares of 0.1p

 

ISIN: GB00BG226J60

 

d)

Nature of the transaction

Acquisition

e)

Price(s) and volume(s)

 

Price(s)

Volume(s)

176.0p

26,705

 

f)

Aggregated information

 

Aggregated volume

 

Price

 

 

26,705

 

£47,000.80

g)

Date of the transaction

21 September 2018

 

h)

Place of the transaction

LONDON STOCK EXCHANGE XLON

 

       

 

Nucleus           

David Ferguson, CEO                                                     Tel: +44 (0)13 1226 9800

Stuart Geard, Chief Financial Officer       

Shore Capital (Nominated Adviser and Broker)         

Hugh Morgan                                                                   Tel: +44 (0)20 7408 4090

Edward Mansfield               

Daniel Bush 

Camarco (Media enquiries)    

Jennifer Renwick                                                             Tel: +44 (0)20 3757 4994

Jake Thomas    


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHLAMBTMBMTBBP

a d v e r t i s e m e n t